Eugin Group (North American operations)→KKR (via IVI-RMA)
Acquisition · Cash · announced Nov 1, 2023
Announced
Nov 1, 2023
Closed
Jan 31, 2024
Economics
Cash()
Pre-deal · pre-deal mark: 2023, year precision · rounding grid ±$100M · IVI-RMA Global press release — Eugin Group acquisition, 2024
Part of KKR/GED Capital €494M (~$534M) acquisition of Eugin from Fresenius; this covers Boston IVF and TRIO
Target
Eugin Group (North American operations)
Fertility · Fertility science
HQ Barcelona, Spain · Founded 1999
Global fertility network including Boston IVF and TRIO (Toronto); 13 labs and 32 satellite offices in North America
- Business Wire - IVI RMA completion announcement (January 31, 2024)
- PitchBook (November 2023) - deal reporting
- Fresenius SE press release (divestiture)
Acquirer
KKR
Healthcare
HQ New York, NY
Global investment firm; major investor in fertility clinic consolidation
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Added Boston IVF (Harvard-affiliated, 13 labs) and TRIO (Toronto) to IVI-RMA network, consolidating North American fertility market leadership
Evidence ladder
Secondary (press / IR)
Business Wire (January 31, 2024)
Tertiary (trade / analyst)
PitchBook (November 2023)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- Part of KKR/GED Capital €494M (~$534M) acquisition of Eugin from Fresenius; this covers Boston IVF and TRIO
- Pre-deal valuation sourced from: IVI-RMA Global press release — Eugin Group acquisition, 2024. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Fertility
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Indira IVF | BPEA EQT | Jul 28, 2023 | same evidence class | |
| Hamilton Thorne | Astorg | Jul 22, 2024 | same evidence class | |
| Modern Fertility | Ro | May 19, 2021 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| IVI-RMA Global | KKR | Mar 1, 2022 |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Eugin Group (North American operations) (Fertility). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.